Hanjie Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hanjie Zhang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Dongze Mo
Nanjing University
2 shared publications- Hui Wei
Nanjing University
2 shared publications - Qi Sun
Nanjing University
2 shared publications Wanling Liu
Nanjing University
2 shared publications- Xiaomiao Cui
Nanjing University
2 shared publications Xiwen Chen
Nanjing University
2 shared publications
Latest Publications
- 10 November 2026
- Published by American Chemical Society (ACS) in ACS Nano
Biomimetic Nanozyme-Decoys Reprogram Immune Niches to Intercept Colitis-Carcinoma Transition
Colitis-associated colorectal cancer (CAC) arises from chronic inflammatory niches characterized by persistent oxidative stress and dysregulated immune cell recruitment. Current anti-inflammatory therapies provide only transient symptom relief and fail to prevent malignant progression due to their inability to simultaneously mitigate oxidative injury and immune chemotaxis. Our analysis of clinical samples revealed markedly elevated C-X-C motif chemokine ligand 2 (CXCL2) in intestinal tissues from patients with inflammatory bowel disease and CAC, implicating the CXCL2-CXCR2 (C-X-C motif chemokine receptor 2) axis in driving excessive neutrophil and macrophage infiltration and fostering tumorigenesis. Herein, we report a biomimetic nanozyme (PB@ECM) that reprograms inflammatory immune niches to intercept CAC progression. PB@ECM integrates a Prussian blue nanozyme core with genetically engineered macrophage membranes, enabling concurrent scavenging of reactive oxygen species through superoxide dismutase- and catalase-like activities and sequestration of CXCL2 via membrane-displayed CXCR2 receptors. In murine models of colitis and CAC, PB@ECM significantly alleviated intestinal inflammation, suppressed neutrophil and macrophage infiltration, and effectively inhibited colitis-carcinoma transition. Notably, treatment with PB@ECM significantly prolonged survival compared with other groups. By disrupting the pathological crosstalk between oxidative stress and immune chemotaxis, this work establishes a biomimetic nanozyme strategy for preventing inflammation-driven carcinogenesis.
- 10 November 2026
- Published by American Chemical Society (ACS) in ACS Nano
Biomimetic Nanozyme-Decoys Reprogram Immune Niches to Intercept Colitis-Carcinoma Transition
Colitis-associated colorectal cancer (CAC) arises from chronic inflammatory niches characterized by persistent oxidative stress and dysregulated immune cell recruitment. Current anti-inflammatory therapies provide only transient symptom relief and fail to prevent malignant progression due to their inability to simultaneously mitigate oxidative injury and immune chemotaxis. Our analysis of clinical samples revealed markedly elevated C-X-C motif chemokine ligand 2 (CXCL2) in intestinal tissues from patients with inflammatory bowel disease and CAC, implicating the CXCL2-CXCR2 (C-X-C motif chemokine receptor 2) axis in driving excessive neutrophil and macrophage infiltration and fostering tumorigenesis. Herein, we report a biomimetic nanozyme (PB@ECM) that reprograms inflammatory immune niches to intercept CAC progression. PB@ECM integrates a Prussian blue nanozyme core with genetically engineered macrophage membranes, enabling concurrent scavenging of reactive oxygen species through superoxide dismutase- and catalase-like activities and sequestration of CXCL2 via membrane-displayed CXCR2 receptors. In murine models of colitis and CAC, PB@ECM significantly alleviated intestinal inflammation, suppressed neutrophil and macrophage infiltration, and effectively inhibited colitis-carcinoma transition. Notably, treatment with PB@ECM significantly prolonged survival compared with other groups. By disrupting the pathological crosstalk between oxidative stress and immune chemotaxis, this work establishes a biomimetic nanozyme strategy for preventing inflammation-driven carcinogenesis.
- 14 September 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (37) , 25841-25858
A Theranostic Nanozyme for Osteoarthritis Treatment and Glycosaminoglycan-Targeted Diagnosis of Cartilage Pathology
The lack of vascular and neural innervations in cartilage often results in poor drug delivery and penetration, compromising the efficacy of current therapeutics. To tackle this clinical challenge, we designed positively charged manganese-doped CeO2 nanozymes that combine reactive oxygen species (ROS)-scavenging activity with prolonged retention in the joint cavity by taking advantage of the negatively charged cartilage matrix. Integrating coarse-grained molecular dynamics simulations with experimental validation, we identified chondroitin sulfate as the key glycosaminoglycan responsible for mediating the retention of these positively charged nanozymes in the joint cavity. After intra-articular administration, manganese-doped CeO2 promoted cartilage defect repair and subchondral bone remodeling in a rat model within 4 weeks. In addition, benefiting from the multiple enzyme mimicking activity of nanozymes, the peroxidase-like activity of manganese-doped CeO2 was explored to develop a pathological assay to detect the state of cartilage repair. This study establishes an integrated framework combining theoretical modeling with experimental validation to elucidate intra-articular retention mechanisms. The framework enables the rational design of theranostic nanozymes that exploit disease-specific pathological features for both diagnosis and therapy.
- 14 September 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (37) , 25841-25858
A Theranostic Nanozyme for Osteoarthritis Treatment and Glycosaminoglycan-Targeted Diagnosis of Cartilage Pathology
The lack of vascular and neural innervations in cartilage often results in poor drug delivery and penetration, compromising the efficacy of current therapeutics. To tackle this clinical challenge, we designed positively charged manganese-doped CeO2 nanozymes that combine reactive oxygen species (ROS)-scavenging activity with prolonged retention in the joint cavity by taking advantage of the negatively charged cartilage matrix. Integrating coarse-grained molecular dynamics simulations with experimental validation, we identified chondroitin sulfate as the key glycosaminoglycan responsible for mediating the retention of these positively charged nanozymes in the joint cavity. After intra-articular administration, manganese-doped CeO2 promoted cartilage defect repair and subchondral bone remodeling in a rat model within 4 weeks. In addition, benefiting from the multiple enzyme mimicking activity of nanozymes, the peroxidase-like activity of manganese-doped CeO2 was explored to develop a pathological assay to detect the state of cartilage repair. This study establishes an integrated framework combining theoretical modeling with experimental validation to elucidate intra-articular retention mechanisms. The framework enables the rational design of theranostic nanozymes that exploit disease-specific pathological features for both diagnosis and therapy.